80 related articles for article (PubMed ID: 38509243)
1. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Falato C; Tobin NP; Lorent J; Lindström LS; Bergh J; Foukakis T
Mol Oncol; 2016 Apr; 10(4):517-25. PubMed ID: 26651914
[TBL] [Abstract][Full Text] [Related]
2. Obesity and Breast Cancer Metastasis across Genomic Subtypes.
Olsson LT; Walens A; Hamilton AM; Benefield HC; Fleming JM; Carey LA; Hursting SD; Williams KP; Troester MA
Cancer Epidemiol Biomarkers Prev; 2022 Oct; 31(10):1944-1951. PubMed ID: 35973227
[TBL] [Abstract][Full Text] [Related]
3. Age-related clusters and favorable immune phenotypes in breast cancer of the young.
Ingebriktsen LM; Svanøe AA; Sæle AKM; Humlevik ROC; Toska K; Kalvenes MB; Aas T; Heie A; Askeland C; Knutsvik G; Stefansson IM; Akslen LA; Hoivik EA; Wik E
Mod Pathol; 2024 May; ():100529. PubMed ID: 38810731
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies.
Kamposioras K; Vassilakopoulou M; Anthoney A; Bariuoso J; Mauri D; Mansoor W; Papadopoulos V; Dimas K
Pharmacol Ther; 2022 May; 233():108028. PubMed ID: 34755606
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1, breast cancer and ionizing radiation.
Pucci M; Bravatà V; Forte GI; Cammarata FP; Messa C; Gilardi MC; Minafra L
Cancer Genomics Proteomics; 2015; 12(3):143-52. PubMed ID: 25977173
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer.
Godina C; Belting M; Vallon-Christersson J; Isaksson K; Bosch A; Jernström H
Sci Rep; 2024 Mar; 14(1):6675. PubMed ID: 38509243
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-1 accumulation in the tongue cancer tumor microenvironment is significantly associated with poor prognosis: an in-vivo and in-vitro study.
Vered M; Lehtonen M; Hotakainen L; Pirilä E; Teppo S; Nyberg P; Sormunen R; Zlotogorski-Hurvitz A; Salo T; Dayan D
BMC Cancer; 2015 Jan; 15():25. PubMed ID: 25633184
[TBL] [Abstract][Full Text] [Related]
9. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
[TBL] [Abstract][Full Text] [Related]
10. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
[TBL] [Abstract][Full Text] [Related]
11. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
Phakathi B; Dix-Peek T; Van Den Berg E; Dickens C; Nietz S; Cubasch H; Joffe M; Neugut AI; Jacobson JS; Ruff P; Duarte R
Breast Cancer Res Treat; 2023 Aug; 200(3):337-346. PubMed ID: 37266756
[TBL] [Abstract][Full Text] [Related]
12. Activated fibroblasts in cancer: Perspectives and challenges.
Caligiuri G; Tuveson DA
Cancer Cell; 2023 Mar; 41(3):434-449. PubMed ID: 36917949
[TBL] [Abstract][Full Text] [Related]
13. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
de Visser KE; Joyce JA
Cancer Cell; 2023 Mar; 41(3):374-403. PubMed ID: 36917948
[TBL] [Abstract][Full Text] [Related]
14. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Asleh K; Lluch A; Goytain A; Barrios C; Wang XQ; Torrecillas L; Gao D; Ruiz-Borrego M; Leung S; Bines J; Guerrero-Zotano Á; García-Sáenz JÁ; Cejalvo JM; Herranz J; Torres R; Haba-Rodriguez J; Ayala F; Gómez H; Rojo F; Nielsen TO; Martin M
Clin Cancer Res; 2023 Jan; 29(2):389-400. PubMed ID: 36346687
[TBL] [Abstract][Full Text] [Related]
15. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer.
Staaf J; Häkkinen J; Hegardt C; Saal LH; Kimbung S; Hedenfalk I; Lien T; Sørlie T; Naume B; Russnes H; Marcone R; Ayyanan A; Brisken C; Malterling RR; Asking B; Olofsson H; Lindman H; Bendahl PO; Ehinger A; Larsson C; Loman N; Rydén L; Malmberg M; Borg Å; Vallon-Christersson J
NPJ Breast Cancer; 2022 Aug; 8(1):94. PubMed ID: 35974007
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
